Organization | Next Gen Pharma India Pvt. Ltd.

Next Gen Pharma India Pvt. Ltd. Report issue

For profit Phase 3

Founded: Noida India (2004)

Status: No NME R&D (2004)

Organization Overview

First Clinical Trial

2015

NCT02329353

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (10)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus brevis (2 trials)

lactobacillus casei (1 trial)

lactobacillus delbrueckii (2 trials)

lactobacillus plantarum (1 trial)

streptococcus salivarius (1 trial)

vsl #3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Chronic Periodontitis (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Malocclusion (Phase 3)

Periodontitis (Phase 3)

Syndrome (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 10